Alterations of eicosanoids and related mediators in patients with schizophrenia

Dongfang Wang, Xiaoyu Sun, Jingjing Yan, Biao Ren, Bing Cao, Qingbin Lu, Yaqiong Liu, Jing Zeng, Ninghua Huang, Qing Xie, Haiwei Gu, Jingyu Wang

    Research output: Contribution to journalArticle

    5 Citations (Scopus)

    Abstract

    Schizophrenia (SCZ) is a multifactorial psychiatric disorder. Currently, its molecular pathogenesis remains largely unknown, and no reliable test for diagnosis and therapy monitoring is available. Polyunsaturated fatty acids (PUFAs) and their derived eicosanoid signaling abnormalities are relevant to the pathophysiology of schizophrenia. However, comprehensive analysis of eicosanoids and related mediators for schizophrenia is very rare. In this study, we applied a targeted liquid chromatography-mass spectrometry based method to monitor 158 PUFAs, eicosanoids and related mediators from enzyme-dependent or independent pathways, in the serum samples of 109 healthy controls, and 115 schizophrenia patients at baseline and after an 8-week period of antipsychotic therapy. Twenty-three metabolites were identified to be significantly altered in SCZ patients at baseline compared to healthy controls, especially arachidonic acid (AA) derived eicosanoids. These disturbances may be related to altered immunological reactions and neurotransmitter signaling. After 8-week antipsychotic treatment, there were 22 metabolites, especially AA and linoleic acid derived eicosanoids, significantly altered in posttreatment patients. Some metabolites, such as several AA derived prostaglandins, thromboxanes, and di-hydroxy-eicosatrienoic acids were reversed toward normal levels after treatment. Based on univariate analysis and orthogonal partial least-squares discriminant analysis, anandamide, oleoylethanolamine, and AA were selected as a panel of potential biomarkers for differentiating baseline SCZ patients from controls, which showed a high sensitivity (0.907), good specificity (0.843) and excellent area under the receiver operating characteristic curve (0.940). This study provided a new perspective to understand the pathophysiological mechanism and identify potential biomarkers of SCZ.

    Original languageEnglish (US)
    Pages (from-to)168-178
    Number of pages11
    JournalJournal of Psychiatric Research
    Volume102
    DOIs
    StatePublished - Jul 1 2018

    Fingerprint

    Eicosanoids
    Schizophrenia
    Arachidonic Acid
    Unsaturated Fatty Acids
    Antipsychotic Agents
    Biomarkers
    Hydroxy Acids
    Thromboxanes
    Discriminant Analysis
    Linoleic Acid
    Therapeutics
    Least-Squares Analysis
    ROC Curve
    Liquid Chromatography
    Prostaglandins
    Neurotransmitter Agents
    Psychiatry
    Mass Spectrometry
    Enzymes
    Serum

    Keywords

    • Biomarker
    • Eicosanoids
    • Liquid chromatography-mass spectrometry
    • Metabolomics
    • Polyunsaturated fatty acids
    • Schizophrenia

    ASJC Scopus subject areas

    • Psychiatry and Mental health
    • Biological Psychiatry

    Cite this

    Alterations of eicosanoids and related mediators in patients with schizophrenia. / Wang, Dongfang; Sun, Xiaoyu; Yan, Jingjing; Ren, Biao; Cao, Bing; Lu, Qingbin; Liu, Yaqiong; Zeng, Jing; Huang, Ninghua; Xie, Qing; Gu, Haiwei; Wang, Jingyu.

    In: Journal of Psychiatric Research, Vol. 102, 01.07.2018, p. 168-178.

    Research output: Contribution to journalArticle

    Wang, D, Sun, X, Yan, J, Ren, B, Cao, B, Lu, Q, Liu, Y, Zeng, J, Huang, N, Xie, Q, Gu, H & Wang, J 2018, 'Alterations of eicosanoids and related mediators in patients with schizophrenia', Journal of Psychiatric Research, vol. 102, pp. 168-178. https://doi.org/10.1016/j.jpsychires.2018.04.002
    Wang, Dongfang ; Sun, Xiaoyu ; Yan, Jingjing ; Ren, Biao ; Cao, Bing ; Lu, Qingbin ; Liu, Yaqiong ; Zeng, Jing ; Huang, Ninghua ; Xie, Qing ; Gu, Haiwei ; Wang, Jingyu. / Alterations of eicosanoids and related mediators in patients with schizophrenia. In: Journal of Psychiatric Research. 2018 ; Vol. 102. pp. 168-178.
    @article{d6187f81564d48c4ae3cc8a611c2f7e8,
    title = "Alterations of eicosanoids and related mediators in patients with schizophrenia",
    abstract = "Schizophrenia (SCZ) is a multifactorial psychiatric disorder. Currently, its molecular pathogenesis remains largely unknown, and no reliable test for diagnosis and therapy monitoring is available. Polyunsaturated fatty acids (PUFAs) and their derived eicosanoid signaling abnormalities are relevant to the pathophysiology of schizophrenia. However, comprehensive analysis of eicosanoids and related mediators for schizophrenia is very rare. In this study, we applied a targeted liquid chromatography-mass spectrometry based method to monitor 158 PUFAs, eicosanoids and related mediators from enzyme-dependent or independent pathways, in the serum samples of 109 healthy controls, and 115 schizophrenia patients at baseline and after an 8-week period of antipsychotic therapy. Twenty-three metabolites were identified to be significantly altered in SCZ patients at baseline compared to healthy controls, especially arachidonic acid (AA) derived eicosanoids. These disturbances may be related to altered immunological reactions and neurotransmitter signaling. After 8-week antipsychotic treatment, there were 22 metabolites, especially AA and linoleic acid derived eicosanoids, significantly altered in posttreatment patients. Some metabolites, such as several AA derived prostaglandins, thromboxanes, and di-hydroxy-eicosatrienoic acids were reversed toward normal levels after treatment. Based on univariate analysis and orthogonal partial least-squares discriminant analysis, anandamide, oleoylethanolamine, and AA were selected as a panel of potential biomarkers for differentiating baseline SCZ patients from controls, which showed a high sensitivity (0.907), good specificity (0.843) and excellent area under the receiver operating characteristic curve (0.940). This study provided a new perspective to understand the pathophysiological mechanism and identify potential biomarkers of SCZ.",
    keywords = "Biomarker, Eicosanoids, Liquid chromatography-mass spectrometry, Metabolomics, Polyunsaturated fatty acids, Schizophrenia",
    author = "Dongfang Wang and Xiaoyu Sun and Jingjing Yan and Biao Ren and Bing Cao and Qingbin Lu and Yaqiong Liu and Jing Zeng and Ninghua Huang and Qing Xie and Haiwei Gu and Jingyu Wang",
    year = "2018",
    month = "7",
    day = "1",
    doi = "10.1016/j.jpsychires.2018.04.002",
    language = "English (US)",
    volume = "102",
    pages = "168--178",
    journal = "Journal of Psychiatric Research",
    issn = "0022-3956",
    publisher = "Elsevier Limited",

    }

    TY - JOUR

    T1 - Alterations of eicosanoids and related mediators in patients with schizophrenia

    AU - Wang, Dongfang

    AU - Sun, Xiaoyu

    AU - Yan, Jingjing

    AU - Ren, Biao

    AU - Cao, Bing

    AU - Lu, Qingbin

    AU - Liu, Yaqiong

    AU - Zeng, Jing

    AU - Huang, Ninghua

    AU - Xie, Qing

    AU - Gu, Haiwei

    AU - Wang, Jingyu

    PY - 2018/7/1

    Y1 - 2018/7/1

    N2 - Schizophrenia (SCZ) is a multifactorial psychiatric disorder. Currently, its molecular pathogenesis remains largely unknown, and no reliable test for diagnosis and therapy monitoring is available. Polyunsaturated fatty acids (PUFAs) and their derived eicosanoid signaling abnormalities are relevant to the pathophysiology of schizophrenia. However, comprehensive analysis of eicosanoids and related mediators for schizophrenia is very rare. In this study, we applied a targeted liquid chromatography-mass spectrometry based method to monitor 158 PUFAs, eicosanoids and related mediators from enzyme-dependent or independent pathways, in the serum samples of 109 healthy controls, and 115 schizophrenia patients at baseline and after an 8-week period of antipsychotic therapy. Twenty-three metabolites were identified to be significantly altered in SCZ patients at baseline compared to healthy controls, especially arachidonic acid (AA) derived eicosanoids. These disturbances may be related to altered immunological reactions and neurotransmitter signaling. After 8-week antipsychotic treatment, there were 22 metabolites, especially AA and linoleic acid derived eicosanoids, significantly altered in posttreatment patients. Some metabolites, such as several AA derived prostaglandins, thromboxanes, and di-hydroxy-eicosatrienoic acids were reversed toward normal levels after treatment. Based on univariate analysis and orthogonal partial least-squares discriminant analysis, anandamide, oleoylethanolamine, and AA were selected as a panel of potential biomarkers for differentiating baseline SCZ patients from controls, which showed a high sensitivity (0.907), good specificity (0.843) and excellent area under the receiver operating characteristic curve (0.940). This study provided a new perspective to understand the pathophysiological mechanism and identify potential biomarkers of SCZ.

    AB - Schizophrenia (SCZ) is a multifactorial psychiatric disorder. Currently, its molecular pathogenesis remains largely unknown, and no reliable test for diagnosis and therapy monitoring is available. Polyunsaturated fatty acids (PUFAs) and their derived eicosanoid signaling abnormalities are relevant to the pathophysiology of schizophrenia. However, comprehensive analysis of eicosanoids and related mediators for schizophrenia is very rare. In this study, we applied a targeted liquid chromatography-mass spectrometry based method to monitor 158 PUFAs, eicosanoids and related mediators from enzyme-dependent or independent pathways, in the serum samples of 109 healthy controls, and 115 schizophrenia patients at baseline and after an 8-week period of antipsychotic therapy. Twenty-three metabolites were identified to be significantly altered in SCZ patients at baseline compared to healthy controls, especially arachidonic acid (AA) derived eicosanoids. These disturbances may be related to altered immunological reactions and neurotransmitter signaling. After 8-week antipsychotic treatment, there were 22 metabolites, especially AA and linoleic acid derived eicosanoids, significantly altered in posttreatment patients. Some metabolites, such as several AA derived prostaglandins, thromboxanes, and di-hydroxy-eicosatrienoic acids were reversed toward normal levels after treatment. Based on univariate analysis and orthogonal partial least-squares discriminant analysis, anandamide, oleoylethanolamine, and AA were selected as a panel of potential biomarkers for differentiating baseline SCZ patients from controls, which showed a high sensitivity (0.907), good specificity (0.843) and excellent area under the receiver operating characteristic curve (0.940). This study provided a new perspective to understand the pathophysiological mechanism and identify potential biomarkers of SCZ.

    KW - Biomarker

    KW - Eicosanoids

    KW - Liquid chromatography-mass spectrometry

    KW - Metabolomics

    KW - Polyunsaturated fatty acids

    KW - Schizophrenia

    UR - http://www.scopus.com/inward/record.url?scp=85045548778&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=85045548778&partnerID=8YFLogxK

    U2 - 10.1016/j.jpsychires.2018.04.002

    DO - 10.1016/j.jpsychires.2018.04.002

    M3 - Article

    C2 - 29674269

    AN - SCOPUS:85045548778

    VL - 102

    SP - 168

    EP - 178

    JO - Journal of Psychiatric Research

    JF - Journal of Psychiatric Research

    SN - 0022-3956

    ER -